Preclinical and Translational Vaccine Development

IDIQ

Description

Support the National Institute of Allergy and Infectious Diseases (NIAID) development of a safe and efficacious preventive HIV-1 vaccine. NIAID supports a portfolio of preclinical, translational, and clinical research to advance HIV vaccine efforts. The Division of AIDS (DAIDS) supports research programs to discover novel vaccine strategies, assess correlates of immunogenicity and of protections elicited by experimental vaccines and provides an infrastructure for the manufacturing and testing of novel products.

The contracts will support tasks in the following areas:
*Research and Development Product Storage and Shipping
*Safety and Immunogenicity Studies
*Feasibility Studies and Early Manufacturability Assessments
*Analytical Characterization and Method Development
*Process Development, CGMP Manufacturing, and Stability
*Fill-Finish, Packaging, and Labeling
*Scientific, Quality, and Regulatory Support Services

Overview

Ceiling

$364,600,000

Primary Sponsoring Agency

National Institute of Allergy and Infectious Diseases (NIAID) [HHS - NIH]

Who Can Use

One Agency

Primary NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Primary PSC

AN12 - Health R&D Services; Health Care Services; Applied Research

Primary Set Aside

None

Extent Competed

Full And Open Competition

Related Opportunity

PRECLINICAL AND TRANSLATIONAL VACCINE DEVELOPMENT FOR HIV AND OTHER CANDIDATE AGENTS (75N93019R00023)

Preclinical and Translational Vaccine Development awarded by National Institute of Allergy and Infectious Diseases (NIAID) in December 2021 accepts orders through November 2028. The IDIQ has a reported ceiling of $364,600,000, and as of today, $25,603,830 has been obligated through the vehicle with a total reported backlog of $14,472,032. The IDIQ was awarded full & open and has a primary NAICS code of 541715.

Award Hierarchy

Vehicle

Preclinical and Translational Vaccine Development

Indefinite Delivery Vehicles

Prime Contracts

Subcontracts

Status

Period of Performance

12/1/21

Start Date

11/30/28

Ordering Period End Date

55.0% Complete

Task Order Obligations and Backlog

$25.6M

Total Obligated

$25.6M

Current Award

$40.1M

Potential Award

64% Funded

$0.0

Funded Backlog

$14.5M

Total Backlog

Vehicle Award Share

Contractors with greatest percentage of obligations for Preclinical and Translational Vaccine Development

Vehicle Award Share

Federal Award Analysis